4 studies found for:    21498393 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Condition: Metastatic Cancers Other Than Melanoma That Express ESO Antigen
Interventions: Biological: Anti-NY ESO-1 mTCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Aldesleukin
2 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Conditions: Cervical Cancer;   Oropharyngeal Cancer;   Vaginal Cancer;   Anal Cancer;   Penile Cancer
Interventions: Drug: Fludarabine;   Drug: Cycolphosphamide;   Biological: Young TIL;   Drug: Aldesleukin
3 Recruiting T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
Conditions: Metastatic Cancer;   Metastatic Melanoma
Interventions: Biological: Anti-NY ESO-1 TCR CD62L+ cells;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
4 Recruiting Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Conditions: Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma
Interventions: Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Young TIL

Indicates status has not been verified in more than two years